Am J Cancer Res 2013;3(1):34-45
Review Article
Role of heparan sulfatases in ovarian and breast cancer
Ashwani Khurana, Daniah Beleford, Xiaoping He, Jeremy Chien, Viji Shridhar
Department of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Cell Biology,
University of Kan-sas Medical Center, Kansas City, KS, USA
Received December 13, 2012; Accepted January 3, 2013; Epub January 18, 2013; Published January 25, 2013
Abstract: Endosulfatases HSulf-1 and -2 (also referred to as Sulf1 and -2) represent a family of enzymes that modulate heparin
binding growth factor signaling. Heparan sulfatase 1 (HSulf-1) and heparan sulfatase 2 (HSulf-2) are two important 6-O
endosulfatases which remove or edit 6-O sulfate residues of N-glucosamine present on highly sulfated HS. Alteration of
heparan sulfatases have been identified in the context of several cancer types. Many cancer types either exhibit increased or
decreased HSulfs expression at the transcript levels. Specifically, HSulf-1 was found to be downregulated in early-stage ovarian
tumors, hepatocellular carcinoma, and metastatic breast cancer patients. HSulf-2 was found to be upregulated in ductal
carcinoma in situ and invasive ductal carcinoma, whereas limited information is present about HSulf-2 expression in different
stages of ovarian cancers. Here, we review the important role of these sulfatases play in ovarian and breast cancers in terms of
tumorigenesis such as angiogenesis, chemoresistance, apoptosis, growth factor signaling, hypoxia and metastasis. These
recent discoveries have added significant understanding about these sulfate editing enzymes. (ajcr0000166).
Keywords: Ovarian and breast cancer, heparin binding growth factor signaling, tumorigenesis, angiogenesis, chemoresponse
and metastasis
Address all correspondence to:
Dr. Viji Shridhar
Mayo College of Medicine
200 First Street, S.W., 2-46 Stabile
Rochester, MN 55905, USA.
Tel: (507) 2662775; Fax: (507) 266-5193
E-mail: shridhar. vijayalakshmi@mayo.edu
Review Article
Role of heparan sulfatases in ovarian and breast cancer
Ashwani Khurana, Daniah Beleford, Xiaoping He, Jeremy Chien, Viji Shridhar
Department of Experimental Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Cell Biology,
University of Kan-sas Medical Center, Kansas City, KS, USA
Received December 13, 2012; Accepted January 3, 2013; Epub January 18, 2013; Published January 25, 2013
Abstract: Endosulfatases HSulf-1 and -2 (also referred to as Sulf1 and -2) represent a family of enzymes that modulate heparin
binding growth factor signaling. Heparan sulfatase 1 (HSulf-1) and heparan sulfatase 2 (HSulf-2) are two important 6-O
endosulfatases which remove or edit 6-O sulfate residues of N-glucosamine present on highly sulfated HS. Alteration of
heparan sulfatases have been identified in the context of several cancer types. Many cancer types either exhibit increased or
decreased HSulfs expression at the transcript levels. Specifically, HSulf-1 was found to be downregulated in early-stage ovarian
tumors, hepatocellular carcinoma, and metastatic breast cancer patients. HSulf-2 was found to be upregulated in ductal
carcinoma in situ and invasive ductal carcinoma, whereas limited information is present about HSulf-2 expression in different
stages of ovarian cancers. Here, we review the important role of these sulfatases play in ovarian and breast cancers in terms of
tumorigenesis such as angiogenesis, chemoresistance, apoptosis, growth factor signaling, hypoxia and metastasis. These
recent discoveries have added significant understanding about these sulfate editing enzymes. (ajcr0000166).
Keywords: Ovarian and breast cancer, heparin binding growth factor signaling, tumorigenesis, angiogenesis, chemoresponse
and metastasis
Address all correspondence to:
Dr. Viji Shridhar
Mayo College of Medicine
200 First Street, S.W., 2-46 Stabile
Rochester, MN 55905, USA.
Tel: (507) 2662775; Fax: (507) 266-5193
E-mail: shridhar. vijayalakshmi@mayo.edu
| AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 | |  | |  | |  | |  | |  | |  | |  |
American Journal of Cancer Research
| ISSN: 2156-6976 |